Cite

HARVARD Citation

    Lee, D. et al. (n.d.). 631 Development of highly efficacious and safe targeted cancer immunotherapy via IL12-based TMEkine™ platform. Journal for immunotherapy of cancer. p. A667. [Online]. 
  
Back to record